Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

Adial Pharmaceuticals (Nasdaq: ADIL) expanded its executive team and closed the first tranche of a major financing.

Rhea-AI Summary

Adial Pharmaceuticals (Nasdaq: ADIL) expanded its executive team and closed the first tranche of a major financing. New hires Matthew Davidson (CDO) and Julie Saiki (EVP strategy) received inducement restricted stock units and stock options. Adial also closed the first $32 million of an up to $64 million private placement to fund its colon-targeted AhR program.

Positive

• First $32 million tranche of up to $64 million private placement closed
• Financing led by multiple specialist life sciences and institutional investors
• Proceeds intended to advance lead colon-targeted AhR program through key clinical milestones
• New CDO and EVP of strategy appointed to strengthen leadership for AT177 program
• Equity awards have 10-year term options priced at $2.98 per share

Negative

• Inducement restricted stock units and options add potential equity dilution for existing shareholders
• Additional vesting tied to future Milestone Warrant issuances implies further potential dilution from new securities

Argus Jun 16 session

-10.88% close to close Open Argus

Details

News Market Reaction – ADIL

On Jun 16, the day this news came out, ADIL closed 10.88% below the previous close.

Data tracked by StockTitan Argus for the Jun 16 session.

Key Figures

First PIPE tranche: $32 million PIPE size: up to $64 million Option exercise price: $2.98 per share +5 more

First PIPE tranche

$32 million

Closed first tranche of private placement, including conversion of assumed notes

PIPE size

up to $64 million

Total potential private placement previously announced

Option exercise price

$2.98 per share

Inducement stock options for new executives, 10-year term

Davidson RSUs

424,446 units

Restricted stock units granted as employment inducement

Davidson options

424,447 options

Options to purchase common stock as inducement award

Saiki RSUs

132,802 units

Restricted stock units granted as employment inducement

Saiki options

132,802 options

Options to purchase common stock as inducement award

Time-based vesting

3 years

Portion of RSUs and options vest monthly over three years

Historical Context

5 past events · Latest: Jun 11

5 events

1. Jun 11

   Acquisition & financing

   24h Move

   +38.0%

   Acquisition of Azora and up to $64M financing for AT177 UC program.

2. May 11

   Q1 earnings update

   24h Move

   +0.7%

   Q1 2026 results with reduced loss, AD04 strategy update, funding needs.

3. Apr 29

   IP / patent filing

   24h Move

   -0.6%

   New U.S. patent application for AD04 aiming for exclusivity through 2045.

4. Apr 27

   Regulatory program step

   24h Move

   -1.3%

   Submission to FDA CNPV pilot program to potentially accelerate AD04 review.

5. Apr 22

   Manufacturing milestone

   24h Move

   -0.9%

   Completion of AD04 demonstration batch enabling clinical and registration supply.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, stock options, exercise price, Nasdaq Listing Rule 5635(c)(4), +4 more

8 terms

restricted stock units financial

"granted Matthew Davidson and Julie Saiki ... restricted stock units and stock options"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock options financial

"restricted stock units and stock options to purchase Company common stock as an inducement"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"The option awards ... have an exercise price of $2.98 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in reliance on the employment inducement exception to shareholder approval provided under Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

pre-funded warrant financial

"sale and issuance by the Company of each pre-funded warrant and common warrant"

A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.

common warrant financial

"sale and issuance by the Company of each pre-funded warrant and common warrant"

A common warrant is a tradable security that gives its holder the right to buy a company’s common shares at a preset price for a limited time. It matters to investors because exercising warrants can dilute existing ownership and create leverage: holders can benefit if the stock rises above the preset price, while holders of original shares face potential reduction in their percentage stake, similar to more tickets being added to a raffle.

Securities Purchase Agreement financial

"pursuant to that certain Securities Purchase Agreement entered into by and among the Company"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

Exchange Agreement financial

"and that Exchange Agreement entered into by and among the Company and certain noteholders"

A written deal in which two parties agree to swap assets, securities or obligations under set terms—think of it as a formal swap or trade contract. For investors it matters because such agreements can change who owns what, alter a company’s capital structure, affect future cash flows or dilute existing shares, and therefore influence value and risk in a straightforward, contract-driven way.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company’s newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options to purchase Company common stock as an inducement to them becoming employees of the Company in connection with the closing of its business combination with Azora Therapeutics, Inc. (“Azora”), which was previously announced by the Company on June 11, 2026. Additionally, the Company today announced the closing of the first $32 million (including the conversion of outstanding notes assumed in the acquisition of Azora) of its previously announced up to $64 million private placement.

Inducement Awards
As an inducement to Dr. Davidson and Ms. Saiki becoming employees of Adial, Adial granted Dr. Davidson 424,446 restricted stock units and stock options to purchase 424,447 shares of Company common stock and granted Ms. Saiki 132,802 restricted stock units and stock options to purchase 132,802 shares of Company common stock. The option awards granted to Dr. Davidson and Ms. Saiki have an exercise price of $2.98 per share, the closing price of the Company’s common stock on June 12, 2026, and have a ten-year term. The restricted stock units and the options awarded to Dr. Davidson and Ms. Saiki will vest as follows: (i) with respect to 232,417 restricted stock units and options to purchase 232,417 shares of Company common stock granted to Dr. Davidson and 72,719 restricted stock unit and options to purchase 72,719 shares of Company common stock granted to Ms. Saiki, pro rata on a monthly basis over three years commencing on the one month anniversary of the effective grant date thereof and (ii) with respect to 192,029 restricted stock units and options to purchase 192,030 shares of Company common stock granted to Dr. Davidson and 60,083 restricted stock unit and options to purchase 60,083 shares of Company common stock granted to Ms. Saiki, a pro rata portion of such awards will be subject to the same vesting included in (i) upon the sale and issuance by the Company of each pre-funded warrant and common warrant (collectively, the “Milestone Warrants”) to investors pursuant to that certain Securities Purchase Agreement entered into by and among the Company with certain investors on June 11, 2026 and that Exchange Agreement entered into by and among the Company and certain noteholders on June 11, 2026, subject to catch up vesting for any awards that would have otherwise vested prior to issuance of such Milestone Warrants.

The above grants were approved by the Company’s Compensation Committee and Board of Directors and were made as an inducement material to the employees entering into employment with Adial. The grants were made outside of the Company’s equity incentive plans and in reliance on the employment inducement exception to shareholder approval provided under Nasdaq Listing Rule 5635(c)(4), which requires public announcement of inducement awards.

Closing of Private Placement

On June 12, 2026, the Company closed the first $32 million tranche (including the conversion of outstanding notes assumed in the acquisition of Azora) of the up to $64 million private placement that Adial previously announced on June 11, 2026. The financing was led by Coastlands Capital, with participation from Kern Capital, Boxer Capital Management, Stonepine Capital Management, AuGC BioFund and other biotech specialists and institutional investors along with insiders and management.

Jay Kern, Founder and General Partner of Kern Capital, one of the lead investors in the private placement, said, “Kern Capital focuses on differentiated life sciences programs with outstanding management teams and the potential to become market leaders within their indication, all of which we see at Adial. AT177 is a compelling opportunity, and Matt and Julie are exactly the right executives to help advance it.”

The Company would like to thank its investors for their diligence and support, and looks forward to utilizing the proceeds from the private placement to advance its lead colon-targeted AhR program through key clinical milestones and to build value for the Company’s shareholders.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a biopharmaceutical company historically focused on the development of treatments for addictions and related disorders. Following the acquisition of Azora Therapeutics, Adial’s lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. The Company’s historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. Additional information is available at www.adial.com.

Cautionary Note Regarding Forward-Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include, but are not limited to, statements regarding the vesting of the inducement awards, including regarding the Company’s sale and issuance of Milestone Warrants to investors and/or noteholders, and plans to use proceeds from the private placement to advance its lead colon-targeted AhR program through key clinical milestones and to build value for the Company’s shareholders. Any forward-looking statements included herein reflect the Company’s current views, and they involve certain risks and uncertainties, including, among others, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to develop strategic partnership opportunities and maintain collaborations; the Company’s ability to obtain or maintain the capital or grants necessary to fund its research and development activities; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for specific indications; acceptance of the Company’s product candidates in the marketplace and the successful development, marketing or sale of its products; the Company’s ability to maintain its license agreements; the continued maintenance and growth of the Company’s patent estate and its ability to retain its key employees or maintain the Company’s Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. These risks should not be construed as exhaustive and should be read together with the other cautionary statements contained in such reports. Any forward-looking statement speaks only as of the date on which it was initially made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com

Mike Moyer
Managing Director,
LifeSci Advisors, LLC
Phone: (617) 328-4326
Email: mmoyer@lifesciadvisors.co

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive leadership changes did Adial Pharmaceuticals (NASDAQ: ADIL) announce on June 16, 2026?

Adial Pharmaceuticals appointed Matthew Davidson as chief development officer and Julie Saiki as executive vice president of strategy. According to Adial, both executives received inducement restricted stock units and stock options in connection with the Azora Therapeutics business combination and their employment.

How many RSUs and stock options did Matthew Davidson and Julie Saiki receive at Adial (ADIL)?

Matthew Davidson received 424,446 restricted stock units and options to purchase 424,447 shares, while Julie Saiki received 132,802 RSUs and options to purchase 132,802 shares. According to Adial, these equity awards were granted as employment inducements outside existing equity incentive plans.

What are the key terms of Adial Pharmaceuticals' June 2026 PIPE financing for ADIL stock?

Adial closed the first $32 million tranche of an up to $64 million private placement on June 12, 2026. According to Adial, this amount includes conversion of outstanding notes assumed in the Azora acquisition and was led by Coastlands Capital with several specialist biotech investors.

How will Adial Pharmaceuticals use the $32 million private placement proceeds for ADIL shareholders?

Adial plans to use the private placement proceeds to advance its lead colon-targeted AhR program through key clinical milestones. According to Adial, the goal is to build value for shareholders by progressing AT177 and related development activities enabled by this financing.

Who participated in Adial Pharmaceuticals' $32 million private placement announced in June 2026?

The financing was led by Coastlands Capital with participation from Kern Capital, Boxer Capital Management, Stonepine Capital Management, AuGC BioFund, other biotech specialists, institutional investors, insiders, and management. According to Adial, these investors supported the company’s strategy and lead AT177 program.

What are the vesting terms and exercise price of the new Adial (ADIL) executive stock options?

The options have a ten-year term and an exercise price of $2.98 per share, Adial’s June 12, 2026 closing price. According to Adial, portions vest monthly over three years, with additional tranches vesting as Milestone Warrants are sold and issued.

How is Adial's Azora Therapeutics acquisition connected to the June 2026 financing and executive grants for ADIL?

The executive inducement awards and note conversion were linked to Adial’s business combination with Azora Therapeutics. According to Adial, the first $32 million tranche includes conversion of notes assumed in the acquisition and supports advancing the Azora-originated AT177 colon-targeted AhR program.